Antiphospholipid Syndrome (APS)
2
Pipeline Programs
1
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
CP
Trial Timeline
Clinical trial activity over time
2024
2025
2026
2027
Chugai PharmaRAY121
Chugai PharmaRAY121
Clinical Trials (2)
Total enrollment: 288 patients across 2 trials
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
Start: Dec 2024Est. completion: Apr 2027144 patients
Phase 1Enrolling By Invitation
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Start: Aug 2024Est. completion: Jun 2026144 patients
Phase 1Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 288 patients
1 companies competing in this space